What is the dosage of Loftair (Fluticasone) inhaler?

From the Guidelines

The recommended dosage of Loftair inhaler, which contains fluticasone propionate, is 44 mcg/puff, 2 puffs twice daily via a spacer and face mask, as evidenced by the PEAK study 1. This dosage is based on the Prevention of Early Asthma in Kids (PEAK) trial, which was a three-year long, double-blind, randomized, parallel group design trial that treated children ages 2–3 years with a positive modified asthma predictive index (API) with either fluticasone 44 mcg/puff MDI or matching placebo. The study found that during the two-year treatment period, ICS use was associated with a 4.8% greater proportion of episode-free days, a 32.0% lower rate of exacerbations, and a 53.0% reduction in supplementary ICS use 1. Key points to consider when using the Loftair inhaler include:

• Proper technique is essential: shake the inhaler well before use, exhale fully, place the mouthpiece between lips, inhale slowly while pressing down on the canister, hold breath for about 10 seconds, then exhale slowly.
• Rinse your mouth with water after each use to prevent oral thrush, a common side effect.
• Fluticasone is a corticosteroid that works by reducing inflammation in the airways, which helps to control symptoms like wheezing and shortness of breath.
• It may take several days to weeks of regular use before maximum benefit is achieved, so patience and consistency are important. The PEAK study also assessed the potential effects of long-term use of the ICS on growth velocity and found that although symptom control during the treatment period was clearly improved with daily ICS therapy, some side effects from the treatment on linear growth were observed 1.

From the FDA Drug Label

DOSAGE AND ADMINISTRATION Patients should use Fluticasone Propionate Nasal Spray, USP, at regular intervals for optimal effect. Adults The recommended starting dosage in is 2 sprays (50 mcg of fluticasone propionate each) in each nostril once daily (total daily dose, 200 mcg). The same dosage divided into 100 mcg given twice daily (e.g., 8 a.m. and 8 p.m.) is also effective. After the first few days, patients may be able to reduce their dosage to 100 mcg (1 spray in each nostril) once daily for maintenance therapy. Some patients (12 years of age and older) with seasonal allergic rhinitis may find as-needed use of 200 mcg once daily effective for symptom control Adolescents and Children (4 Years of Age and Older) Patients should be started with 100 mcg (1 spray in each nostril once daily). Patients not adequately responding to 100 mcg may use 200 mcg (2 sprays in each nostril). Once adequate control is achieved, the dosage should be decreased to 100 mcg (1 spray in each nostril) daily The maximum total daily dosage should not exceed 2 sprays in each nostril (200 mcg/day).

The FDA drug label does not answer the question about Loftair inhaler dosage, as it appears to be discussing the dosage for a nasal spray, not an inhaler 2.

From the Research

Loftair Inhaler Dosage

There is no direct information available on the Loftair inhaler dosage in the provided studies.

Available Information on Similar Inhalers

• The studies discuss the use of phosphodiesterase 4 (PDE4) inhibitors, such as roflumilast, for the treatment of chronic obstructive pulmonary disease (COPD) and asthma 3, 4, 5, 6, 7.
• Roflumilast is an oral PDE4 inhibitor that has been shown to reduce exacerbations and improve lung function in patients with COPD, particularly those with chronic bronchitis and frequent exacerbations 4, 5.
• Inhaled PDE4 inhibitors, such as tanimilast, are being developed to reduce systemic side effects and maximize therapeutic effects in the lung 3.
• Dual PDE3/4 inhibitors, such as RPL554/ensifentrine, are also being developed for the treatment of COPD and have shown promising results in clinical trials 6.

Key Points to Consider

• The dosage of Loftair inhaler is not specified in the provided studies.
• PDE4 inhibitors, such as roflumilast, have been shown to be effective in reducing exacerbations and improving lung function in patients with COPD.
• Inhaled PDE4 inhibitors and dual PDE3/4 inhibitors are being developed to improve therapeutic effects and reduce side effects.